{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679761400064.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2492/jsir1981.20.247"}},{"identifier":{"@type":"NAID","@value":"130003856686"}},{"identifier":{"@type":"NAID","@value":"10009361174"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2000236246"}}],"dc:title":[{"@language":"en","@value":"<I>Relationship between selective COX-2 inhibition and tissue selectivity of prostaglandin biosynthesis inhibition of zaltoprofen</I>"},{"@value":"Zaltoprofenのcyclooxygenase阻害作用の選択性とprostaglandin生合成抑制作用の組織選択性との関連"}],"description":[{"type":"abstract","notation":[{"@language":"en","@value":"The tissue selectivity of zaltoprofen (ZP) and other non-steroidal anti-inflammatory drugs (NSAIDs), against prostaglandin (PG) biosynthesis on inflammatory site and stomach was investigated from the viewpoint of eyclooxygenase (COX) enzyme, anti-carrageenin-induced edema and ulcerogenic activity. All the drugs tested inhibited COX-1 and COX-2 activities using the refined enzymes in the concentration-dependent manner. The selectivity ratio of CO-1/CG-2 inhibition was the order that ZP (6.56) >etodolac (EL, 3.93) >diclofenac sodium (DF, 1.96) >loxoprofen (SRS-<I>trans</I>-alcohol form) (1.90) >indomethacin (IM, 0.16) . Selectivity for COX-2 of ZP was superior to those of other NSAIDs. The inhibitory effects of ZP, loxoprofen sodium (LP), EL and IM on the PGE<SUB>2</SUB> content in the carrageenin-air pouch and the PGE<SUB>2</SUB> release from the gastric ucosa of the same rat were determined. At the doses of NSAIDs which inhibited the PGE<SUB>2</SUB> biosynthesis at the same degree in the carrageenin-air pouch, ZP hardly inhibited the PGE<SUB>2</SUB> release from the gastric mucosa. EL and LP inhibited the PGE<SUB>2</SUB> biosynthesis at the same degree between inflammatory site and gastric mucosa. On the other hand, IM markedly inhibited the PGE<SUB>2</SUB> release. All NSAIDs tested inhibited the carrageenin-induced edema in the dose-dependent manner, ED<SUB>50</SUB> values of ZP, EL, LP, DF and IM were 2.4, 13.8, 1.9, 6.4 and 3.7 mg/kg, p.o., respectively. On the other hand, ulcerogenic activity (UD<SUB>50</SUB> value) of ZP, EL, LP, DF and INI were 45.3, 12.5, 5.9, 4.1 and 3.3 mg/kg, p.o., respectively. The good correlation between UD<SUB>50</SUB> values and the inhibitory activity of the PG release from the gastric mucosa of NSAIDs was noted.<BR>From these results, it was found that the inhibitory activity of NSAIDs on the PGE<SUB>2</SUB> release in the stomach correlated well with the selectivity ratio of COX-1/COX-2 inhibition using enzymes and ulcerogenic activity. So, it was suggested that the selectivities for COX-2 of NSAIDs are associated with anti-inflammatory effects and ulcerogenic activity. Also, it was found that ZP has more selectivity for COX-2 and the PG biosynthesis in the inflammatory site compared with other NSAIDs, which were used in the present study. These properties of ZP were seemed to be contributed to the lower ulcerogenic activity on clinical uses."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410009221691632128","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000254448299"},{"@type":"NRID","@value":"9000000843176"},{"@type":"NRID","@value":"9000254451786"}],"foaf:name":[{"@language":"en","@value":"Nishioka Koichiro"},{"@language":"ja","@value":"西岡 浩一郎"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Research Laboratories, Nippon Chemiphar Co., Ltd."},{"@language":"ja","@value":"日本ケミファ株式会社研究所"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001204271097090","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000000843177"}],"foaf:name":[{"@language":"en","@value":"Uchida Aoi"},{"@language":"ja","@value":"内田 あおい"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Research Laboratories, Nippon Chemiphar Co., Ltd."},{"@language":"ja","@value":"日本ケミファ株式会社研究所"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221691632132","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000000843178"},{"@type":"NRID","@value":"9000254451788"}],"foaf:name":[{"@language":"en","@value":"Kunigami Minako"},{"@language":"ja","@value":"國上 美奈子"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Research Laboratories, Nippon Chemiphar Co., Ltd."},{"@language":"ja","@value":"日本ケミファ株式会社研究所"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221691632133","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000000843179"},{"@type":"NRID","@value":"9000254451789"}],"foaf:name":[{"@language":"en","@value":"Matsukura Hitoshi"},{"@language":"ja","@value":"松倉 均"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Research Laboratories, Nippon Chemiphar Co., Ltd."},{"@language":"ja","@value":"日本ケミファ株式会社研究所"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221691632131","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000004730493"},{"@type":"NRID","@value":"9000254448300"},{"@type":"NRID","@value":"9000254451790"}],"foaf:name":[{"@language":"en","@value":"Hirate Kenji"},{"@language":"ja","@value":"平手 謙二"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Research Laboratories, Nippon Chemiphar Co., Ltd."},{"@language":"ja","@value":"日本ケミファ株式会社研究所"}]},{"@id":"https://cir.nii.ac.jp/crid/1410009221691632129","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000000344750"},{"@type":"NRID","@value":"9000254448301"},{"@type":"NRID","@value":"9000254451791"},{"@type":"NRID","@value":"9000258418550"}],"foaf:name":[{"@language":"en","@value":"Saitoh Terunobu"},{"@language":"ja","@value":"斎藤 輝信"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Institute of Rheumatology, Tokyo Women's Medical College"},{"@language":"ja","@value":"東京女子医科大学附属膠原病リウマチ痛風センター"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03894290"},{"@type":"EISSN","@value":"18844006"},{"@type":"NCID","@value":"AN00357213"}],"prism:publicationName":[{"@language":"en","@value":"Ensho"},{"@language":"ja","@value":"炎症"},{"@language":"en","@value":"Ensho"},{"@language":"ja","@value":"炎症"}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society of Inflammation and Regeneration"},{"@language":"ja","@value":"日本炎症・再生医学会"}],"prism:publicationDate":"2000","prism:volume":"20","prism:number":"3","prism:startingPage":"247","prism:endingPage":"255"},"reviewed":"false","url":[{"@id":"https://search.jamas.or.jp/link/ui/2000236246"}],"availableAt":"2000","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=%3CI%3Ezaltoprofen%3C/I%3E","dc:title":"<I>zaltoprofen</I>"},{"@id":"https://cir.nii.ac.jp/all?q=%3CI%3ENSAIDs%3C/I%3E","dc:title":"<I>NSAIDs</I>"},{"@id":"https://cir.nii.ac.jp/all?q=%3CI%3Ecyclooxygenase%3C/I%3E","dc:title":"<I>cyclooxygenase</I>"},{"@id":"https://cir.nii.ac.jp/all?q=%3CI%3Eprostaglandin%3C/I%3E","dc:title":"<I>prostaglandin</I>"},{"@id":"https://cir.nii.ac.jp/all?q=%3CI%3Etissue%20selectivity%3C/I%3E","dc:title":"<I>tissue selectivity</I>"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011145220307200","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic."}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146270601216","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing."}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043748711680","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"Pharmacological analysis of cyclooxygenase-1 in inflammation"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268748219264","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205181319040","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"<I>Selective prostaglandin biosynthesis inhibition of zaltoprofen at the inflammatory site</I>"},{"@value":"Zaltoprofenの炎症部位選択的プロスタグランジン生成抑制作用"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009751776497792","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"新規抗炎症薬(±)-2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid(Zaltoprofen)のラットにおける胃粘膜障害作用およびProstaglandin E_2含量に及ぼす影響 ; Loxoprofen sodiumとの比較"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572701707741312","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"(±)-2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid(CN-100)のプロスタグランジン生合成に対する作用"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854174757059200","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"(±)-2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid(CN-100)の抗炎症および鎮痛作用"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854176706630272","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"新規抗炎症薬Zaltoprofenのラット胃腸粘膜に対する影響"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854176734831872","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Analgesic effects of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135651661981312","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"慢性関節リウマチに対するRAK-591の臨床評価-indomethacinを対照薬とした多施設二重盲検比較試験"}]},{"@id":"https://cir.nii.ac.jp/crid/1571417126615216768","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological investigations of the new antiinflammatory agent 2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid, 1st communication ; Inhibitory effects on rat paw edema"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698601656702592","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of cyclooxygenase-1 and-2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980074645790848","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"変形性膝関節症におけるCN-100の薬効検定"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261549622497664","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Radioimmunoassay measurement of prostaglandins E, A and F in human plasma"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261551545348608","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological investigations of the new antiinflammatory agent 2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid, 3rd communication ; Inhibitory effects on leukocyte emigration and proliferation of granulation"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543024599209344","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"COX-1 and COX-2 ; Toward the development of more selective NSAIDs"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543024599211264","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"慢性関節リウマチに対するCN-100の長期投与試験"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824499575918720","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"ザルトプロフェン(ペオン錠80)の炎症組織移行性"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824499575921024","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Difference in the anti-inflammatory effect of indomethacin between acute and chronic stages of carrageenin-induced inflammation"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824501498769920","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological investigations of the new antiinflammatory agent 2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid, 4th communication ; Inhibitory effects on rat adjuvant arthritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105974993187584","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Preemptive analgesia by zaltoprofen that inhibits bradykinin action and cyclooxygenase in a post-operative pain model"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105976475480576","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological investigations of the new antiinflammatory agent 2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid, 5th communication ; Antiplatelet effect of the drug and antiinflammatory effect of its main metabolites"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668924113404288","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"慢性関節リウマチに対するCN-100の薬効検定"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668926255508992","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"慢性関節リウマチに対するCS-600(loxoprofen sodium)の薬効効果"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668926428901888","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacological investigations of the new antiinflammatory agent 2-(10, 11-dihydro-10-oxodibenzo [b,f] thiepin-2-yl)propionic acid, 2nd communication ; Inhibitory effects on acute inflammation and prostaglandin-related reactions"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400574448000","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"非ステロイド性抗炎症薬Zaltoprofenのシクロオキシゲナーゼ-2選択的阻害作用"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950401404042624","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Analgesic and anti-inflammatory effects of 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl) propionic acid in rat and mouse"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231874459584512","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Distribution and expression of cyclooxygenase(COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231875298951680","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231876402949888","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"腰痛症,頚肩腕症候群,肩関節周囲炎に対するCN-100の臨床評価-インドメタシンを対照薬とした多施設二重盲検比較試験-"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0035875321"},{"@type":"CROSSREF","@value":"10.2492/jsir1981.20.247"},{"@type":"CIA","@value":"10009361174"},{"@type":"CIA","@value":"130003856686"}]}